BC Platforms today announced that it has signed a partnership with Auria Biobank to implement and develop a genomic data management system. BC Platforms’ system enables biobanks to efficiently integrate their sample management process with real time clinical information and genomic data.
For nearly a hundred years, public health care in Finland has collected millions of human tissue samples that can be linked to data from hospital records and National Health Care registers. This combination of samples and data creates a distinctive asset for the development of personalized medicine. Utilization of this unique resource is possible through Auria Biobank, which is Finland’s first clinical biobank. As a part of the agreement, the ongoing maintenance of the Auria-developed system will transfer to BC Platforms and may also be made available to other biobanks.
“The goal in the future is to integrate genomic data with clinical information to further medical research and innovation. We hope that this provides a research and innovation platform to improve clinical decision making to deliver better patient outcomes and yield more personalized healthcare in the future in Finland. We hope that Finland will continue to be at the forefront of this translational approach,” commented Heli Salminen-Mankonen, Director of Auria Biobank.
“Medical research needs large population-based sample collection to improve diagnostics, drug discovery and new treatment methods. Because the data is complicated and there’s lots of it, the data management system needs to be sophisticated enough to handle all of it efficiently. BC Platforms’ data management systems are used at top-tier institutions around the world and we are delighted to be working in a new partnership with Auria Biobank, ” says Timo Kanninen, Chief Architect at BC Platforms.
About BC Platforms
BC Platforms is a world leader in providing powerful genomic data management solutions to address some of the biggest healthcare challenges today by leveraging the convergence of genomics and information technologies. Founded in 1997, the Company has a strong scientific heritage underpinned by 18 years of working in close collaboration with a network of leading researchers, developers, manufacturers and vendors. Our high performing genomic data management platform enables flexible data integration, secure analysis and interpretation of molecular and clinical information. BC Platforms’ vision is to revolutionize drug development and clinical decision-making to bring personalized medicines to patients.
Our management team consists of industry leaders with over 90 years of combined experience in life sciences, computational biology and industrial technology. We currently provide solutions to over 50 leading international institutions in 18 countries including top-tier academic and hospital research groups, major pharmaceutical and agricultural companies. BC Platforms has global operations with its research and development located in Helsinki, Finland, and sales and marketing based in Basel, London, Boston, and Vancouver.
About Auria Biobank
Auria Biobank is Finland’s first clinical biobank. The biobank was established by the University of Turku and the hospital districts of Southwest Finland, Satakunta and Vaasa. The biobank’s activities are guided by the Finnish Biobank Act, which entered into force in autumn 2013. The Biobank Act secures the rights of the donor and improves researchers’ prerequisites for using the sample collections. In accordance with the Biobank Act, samples and personal data can, with the donor’s consent, be collected and saved in biobanks for future research purposes.